Microsoft Word search phase 3 Title Page Amendment

Ophthalmology 2006 Sep;113(9):1488-98. 

---

Section 4B - Study Objectives/Background and Significance (Phase 3 - 12/2010) 
Section 4B - Page 17 
 Cohort 
Study
 
 
46.
 
U.S.Renal Data System. USRDS 2009 Annual Data Report: Atlas of End-Stage Renal 
Disease in the United States. Bethesda, MD: National Institutes of Health, Natinal Institute 
of Diabetes and Digestive and Kidney Diseases; 2009.  
47.
 
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the 
risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004 Sep 
23;351(13):1296-305. 
48.
 
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK 
Prospective Diabetes Study (UKPDS) Group. Lancet 1998 Sep 12;352(9131):837-53. 
49.
 
Anderson EJ, Richardson M, Castle G, Cercone S, Delahanty L, Lyon R, Mueller D, 
Snetselaar L. Nutrition interventions for intensive therapy in the Diabetes Control and 
Complications Trial. The DCCT Research Group. J Am Diet Assoc 1993 Jul;93(7):768-72. 
50.
 
Chavers BM, Mauer SM, Ramsay RC, Steffes MW. Relationship between retinal and 
glomerular lesions in IDDM patients. Diabetes 1994 Mar;43(3):441-6. 
51.
 
Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM. Effects 
of blood pressure level on progression of diabetic nephropathy: results from the RENAAL 
study. Arch Intern Med 2003 Jul 14;163(13):1555-65. 
52.
 
Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Batlle D. Increase in 
nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J 
Med 2002 Sep 12;347(11):797-805. 
53.
 
Fried LF, Forrest KY, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipid modulation in 
insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes 
Complications 2001 May;15(3):113-9. 
54.
 
Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein 
RL. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. 
Kidney Int 2003 Sep;64(3):817-28. 
55.
 
Astrup AS, Tarnow L, Pietraszek L, Schalkwijk CG, Stehouwer CD, Parving HH, Rossing 
P. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or 
without diabetic nephropathy followed for 10 years: association with mortality and decline 
of glomerular filtration rate. Diabetes Care 2008 Jun;31(6):1170-6. 
56.
 
Jorsal A, Tarnow L, Frystyk J, Lajer M, Flyvbjerg A, Parving HH, Vionnet N, Rossing P. 
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with 
type I diabetes and diabetic nephropathy. Kidney Int 2008 Sep;74(5):649-54. 
57.
 
Dalla VM, Mussap M, Gallina P, Bruseghin M, Cernigoi AM, Saller A, Plebani M, Fioretto 
P. Acute-phase markers of inflammation and glomerular structure in patients with type 2 
diabetes. J Am Soc Nephrol 2005 Mar;16 Suppl 1:S78-S82. 

---

Section 4B - Study Objectives/Background and Significance (Phase 3 - 12/2010) 
Section 4B - Page 18 
 Cohort 
Study
 
 
58.
 
Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P. 25-
hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol 
2009 Dec;20(12):2631-9. 
59.
 
de B, I, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels 
and albuminuria in the Third National Health and Nutrition Examination Survey 
(NHANES III). Am J Kidney Dis 2007 Jul;50(1):69-77. 
60.
 
Kostraba JN, Dorman JS, Orchard TJ, Becker DJ, Ohki Y, Ellis D, Doft BH, Lobes LA, 
LaPorte RE, Drash AL. Contribution of diabetes duration before puberty to development of 
microvascular complications in IDDM subjects. Diabetes Care 1989 Nov;12(10):686-93. 
61.
 
Bognetti E, Calori G, Meschi F, Macellaro P, Bonfanti R, Chiumello G. Prevalence and 
correlations of early microvascular complications in young type I diabetic patients: role of 
puberty. J Pediatr Endocrinol Metab 1997 Nov;10(6):587-92. 
62.
 
Lawson ML, Sochett EB, Chait PG, Balfe JW, Daneman D. Effect of puberty on markers 
of glomerular hypertrophy and hypertension in IDDM. Diabetes 1996 Jan;45(1):51-5. 
63.
 
Olsen BS, Sjolie AK, Hougaard P, Johannesen J, Marinelli K, Jacobsen BB, Mortensen 
HB. The significance of the prepubertal diabetes duration for the development of 
retinopathy and nephropathy in patients with type 1 diabetes. J Diabetes Complications 
2004 May;18(3):160-4. 
64.
 
Drummond KN, Kramer MS, Suissa S, Levy-Marchal C, Dell'Aniello S, Sinaiko A, Mauer 
M. Effects of duration and age at onset of type 1 diabetes on preclinical manifestations of 
nephropathy. Diabetes 2003 Jul;52(7):1818-24. 
65.
 
Amin R, Turner C, van AS, Bahu TK, Watts A, Lindsell DR, Dalton RN, Dunger DB. The 
relationship between microalbuminuria and glomerular filtration rate in young type 1 
diabetic subjects: The Oxford Regional Prospective Study. Kidney Int 2005 
Oct;68(4):1740-9. 
66.
 
Ishimura E, Taniwaki H, Tsuchida T, Obatake N, Emoto M, Shoji T, Shioi A, Inaba M, 
Nishizawa Y. Urinary albumin excretion associated with arterial wall stiffness rather than 
thickness in type 2 diabetic patients. J Nephrol 2007 Mar;20(2):204-11. 
67.
 
Yokoyama H, Aoki T, Imahori M, Kuramitsu M. Subclinical atherosclerosis is increased in 
type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and 
pulse wave velocity. Kidney Int 2004 Jul;66(1):448-54. 
68.
 
Maahs DM, Snively BM, Bell RA, Dolan L, Hirsch I, Imperatore G, Linder B, Marcovina 
SM, Mayer-Davis EJ, Pettitt DJ, Rodriguez BL, Dabelea D. Higher prevalence of elevated 
albumin excretion in youth with type 2 than type 1 diabetes: the SEARCH for Diabetes in 
Youth study. Diabetes Care 2007 Oct;30(10):2593-8. 

---

Section 4B - Study Objectives/Background and Significance (Phase 3 - 12/2010) 
Section 4B - Page 19 
 Cohort 
Study
 
 
69.
 
Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, 
Sosenko JM, Ziegler D. Diabetic neuropathies: a statement by the American Diabetes 
Association. Diabetes Care 2005 Apr;28(4):956-62. 
70.
 
Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to 
management. Pharmacol Ther 2008 Oct;120(1):1-34. 
71.
 
Allen C, Shen G, Palta M, Lotz B, Jacobson R, D'Alessio D. Long-term hyperglycemia is 
related to peripheral nerve changes at a diabetes duration of 4 years. The Wisconsin 
Diabetes Registry. Diabetes Care 1997 Jul;20(7):1154-8. 
72.
 
Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes 
Care 2010 Feb;33(2):434-41. 
73.
 
Pop-Busui R, Low PA, Waberski BH, Martin CL, Albers JW, Feldman EL, Sommer C, 
Cleary PA, Lachin JM, Herman WH. Effects of prior intensive insulin therapy on cardiac 
autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and 
Complications Trial/Epidemiology of Diabetes Interventions and Complications study 
(DCCT/EDIC). Circ 2009 Jun 9;119(22):2886-93. 
74.
 
Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent 
hypoglycemia impairs autonomic cardiovascular function: implications for rigorous 
glycemic control. Diabetes 2009 Feb;58(2):360-6. 
75.
 
Prince CT, Secrest AM, Mackey RH, Arena VC, Kingsley LA, Orchard TJ. Cardiovascular 
autonomic neuropathy, HDL cholesterol, and smoking correlate with arterial stiffness 
markers determined 18 years later in type 1 diabetes. Diabetes Care 2010 Mar;33(3):652-7. 
76.
 
Ziegler D, Zentai CP, Perz S, Rathmann W, Haastert B, Doring A, Meisinger C. Prediction 
of mortality using measures of cardiac autonomic dysfunction in the diabetic and 
nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care 2008 
Mar;31(3):556-61. 
77.
 
Ziegler D, Gries FA, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy. 
Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes